Aberrant DNA methylation of the promoter region is a key mechanism for inactivation of genes that suppress tumorigenesis. Genes that are involved in every step of tumor formation can be silenced by this mechanism. Inhibitors of DNA methylation, such as 5-azadeoxycytidine (5AZA), can reverse this epigenetic event suggesting a potential use in cancer therapy. The structure of chromatin can also play an important role with respect to the regulation of gene expression. Chromatin containing hypoacetylated lysines in histones has a compact structure that is repressive for transcription. Inhibitors of histone deacetylase (HDAC) can convert chromatin to an open structure and activate certain genes that inhibit tumor growth. These HDAC inhibitors also have potential in cancer therapy. A 'cross-talk' between DNA methylation and histone deacetylation can occur and work in concert to silence gene expression. The molecular mechanism involves the attachment of a methylated CpG binding protein (MBP) to the methylated promoters and its recruitment of HDAC to form a complex that suppresses transcription. These two epigenetic modifications represent an interesting target for therapeutic intervention using 5AZA and HDAC inhibitors. These agents in combination have been shown to produce a synergistic reactivation of tumor suppressor genes and an enhanced antineoplastic effect against tumor cells, and should be investigated as a novel form of epigenetic therapy for cancer.
Introduction
Epigenetics is described as a heritable change in gene expression without an alteration in the DNA sequence. Research in the past 10 years indicates that epigenetic changes play an important role in tumorigenesis. The major epigenetic changes that take place during the development of cancer are the aberrant DNA methylation of genes that suppress tumorigenesis and histone modifications of chromatin. In this review, the major elements involved in this process will be summarized.
For more details see the excellent reviews recently published on cancer epigenetics (Baylin, 2002; Jones and Baylin, 2002; Nephew and Huang, 2003) .
DNA methylation and cancer
In normal cells, the pattern of DNA methylation is conserved after DNA replication and cell division by the methylation of cytosine by a maintenance DNA methylase (DNMT1). DNA methylation of genes occurs primarily in the promoter region that contain CpG islands, which are defined as a 1 kb stretch of DNA that contains this sequence at a higher frequency than the rest of the genome. The methylation of CpG islands in the promoter region silences gene expression and is a normal event that occurs in cells to regulate gene expression. However, when aberrant DNA methylation of tumor suppressor genes occurs in tumors, it is implicated in neoplastic transformation. The aberrant methylation of genes that suppress tumorigenesis appears to occur early in tumor development and increases progressively, eventually leading to the malignant phenotype. Genes involved in every step of tumorigenesis can be silenced by this epigenetic mechanism (Table 1 ). Genomic screening of 98 different primary human tumors has revealed that on an average there exist about 600 aberrantly methylated CpG islands in each tumor (Costello et al., 2000) . Many of these methylated CpG islands are present in genomic regions containing genes that have not yet been identified and may play an important role in tumorigenesis.
Since tumor suppressor genes have two alleles, in the model proposed by Knudsen (1971) , both alleles have to be inactivated prior to tumor formation. Many tumor suppressor genes have been identified by chromosomal analysis that showed frequent loss of heterozygosity (LOH). However, the inactivation of the second allele was not always understood, until recent research demonstrated that this inactivation can occur by aberrant DNA methylation (reviewed by Jones and Laird, 1999) .
Possible mechanisms that produce aberrant DNA methylation
It is not clear what are the molecular events that lead to aberrant methylation. There are several hypotheses. It is possible that aberrant promoter hypermethylation is due to the infidelity of DNMT1. The substrate for this DNA methylase is hemimethylated DNA. Methylation occurs immediately after DNA replication with the primary function to ensure that the identical methylation pattern of the parental cell is passed on to each daughter cell. DNMT1 is part of a multiprotein DNA replication complex , which may be prone to methylation errors. It is known that the human DNA polymerases replicate genomic DNA with very high fidelity, but do commit errors at a very low frequency (Kunkel and Bebenek, 2000) . Does this also occur for DNMT1? In accordance with this hypothesis is the steady increase in aberrant DNA methylation that occurs with age (reviewed by Issa, 1999) and the progressive increase in the number of methylated CpGs that occurs for some cancer-related genes (Graff et al., 2000) .
Other DNA methylases that could be involved in aberrant DNA methylation are the de novo methylating enzymes DNMT3a and DNMT3b. These enzymes use unmethylated DNA as their template and play an important role in embryonic development (Okano et al., 1999; Li, 2002) . It is not known what controls the specificity of these enzymes, but if they target the wrong CpG sequence, they could contribute to aberrant gene silencing by methylation.
The third possible mechanism responsible for gene hypermethylation could be due to a faulty repair mechanism of aberrantly methylated DNA. A human DNA demethylase has been identified (Ramchandani et al., 1999) . This demethylase has the potential to function as a repair enzyme, which has the potential to correct aberrantly methylated CpG sequences. The factors that control the template specificity of DNA demethylase have not been identified and only future research will clarify its role in the regulation of cell growth and differentiation.
A fourth possible event to produce hypermethylation of CpG islands is related to chromosomal remodeling and implicates the aberrant methylation of lysine-9 of histone-3 in nucleosomes by histone methyltransferase. Histone methylation was proposed to precede and possibly direct DNA methylation (Bachman et al., 2003) . This aspect is discussed in more detail below.
Aberrant DNA methylated genes have been identified in each step of tumorigenesis
In an excellent review on tumorigenesis, Hanahan and Weinberg (2000) have pointed out the major hallmarks of cancer. They propose that most cancers have acquired the same set of capabilities during their development. These capabilities are: (1) self-sufficiency in growth signals; (2) evading apoptosis; (3) insensitivity to antigrowth signals; (4) tissue invasion and metastasis; (5) sustained angiogenesis; and (6) limitless replicative potential. In addition, they state that the enabling characteristic of genome instability facilitates tumor development. A large number of cancer-related genes that are silenced by aberrant DNA methylation have been identified (Tsou et al., 2002) . Many of these genes fit into one or more of the different hallmarks of cancer (Table 1 ). This long list of cancer-related genes plus the findings by genomic screening of a large number of aberrantly methylated CpG islands in different types of tumors (Costello et al., 2000; Shi et al., 2002; Suzuki et al., 2002) indicate that epigenetic events play a key role in tumorigenesis. (2000).
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Chromatin structure and gene expression
Chromatin remodeling also plays an important role in the regulation of expression of certain genes. The basic unit of chromatin is the nucleosome, which consists of 146 base pairs of DNA wrapped around a histone octomer. Modification of the N-terminal group of lysine in histones by acetylation or deacetylation changes the configuration of nucleosomes. The positive charge on unacetylated lysines in the histones is attracted to the negatively charged DNA producing a compact chromatin state that is repressive for transcription. On the other hand, acetylation of the lysines by histone acetylase removes their positive charge and results in an open chromatin structure, which facilitates gene transcription. Histone deacetylase (HDAC) removes the acetyl groups from lysine, which reverses this process and silences gene expression. Aberrant deacetylation of histones in nucleosomes is probably due to dysregulation of the specificity of HDAC and may be associated with neoplastic transformation. For example, gene translocations in some types of leukemia can generate fusion proteins that recruit HDAC and bind to promoters to silence genes involved in differentiation (reviewed by Johnstone, 2002) . The importance of histone modifications in cancer is illustrated by the marked antitumor activity of different inhibitors of HDAC, both in animal models and in preliminary clinical trials Johnstone, 2002) . This aspect is illustrated by the interesting report that the HDAC inhibitor, phenylbutyrate, in combination with retinoic acid induced a complete remission in a patient with acute promyleocytic leukemia resistant to retinoid therapy (Warrell et al., 1998) . The molecular mechanism of action of HDAC inhibitors is related to their activation of a subset of genes that can produce cell cycle arrest, induce differentiation or apoptosis in tumor cells Johnstone, 2002) . Microarray analysis has shown that inhibitors of HDAC can reactivate a subset of genes, but not genes that contain hypermethylated CpG islands, which are only reactivated by an inhibitor of DNA methylation, 5AZA (Suzuki et al., 2002) .
The methylation of lysine in histones by specific histone methylases is also implicated in changes in chromatin structure and gene regulation. The methylation of lysine-4 in histone-3 in nucleosomes is associated with an open chromatin configuration and gene expression. On the other hand, the methylation of lysine-9 in histone-3 is associated with condensed and repressive chromatin. This histone modification and the acetylation/deacetylation of histones to influence gene expression is called the histone code (Jenuwein and Allis, 2001) . A hypermethylated promoter is surrounded by methylated lysine-9 in histone-3, whereas an unmethylated promoter is surrounded by methylated lysine-4 in histone-3 (Fahrner et al., 2002) . Treatment of tumor cells with 5AZA reduces the level of methylated lysine-9 in histone-3 and increases the level of methylated lysine-4 in histone-3 in the promoter region of genes silenced by aberrant DNA methylation (Nguyen et al., 2002) .
Cross-talk between DNA methylation and histone code
Research has shown that a cross-talk between DNA methylation and the histone code exists. This interaction was indicated by the observation that the attachment of the 5-methyl-cytosine binding protein (MBP) to a methylated promoter results in the recruitment of HDAC ). It appears that the gene silencing is related to three key events: the attachment of MBP interferes with the binding of transcription factors to the promoter, the compaction of the chromatin structure due to histone deacetylation by HDAC and the methylation of lysine-9 of histone 3 (Figure 1) .
The importance of the interaction between these epigenetic modifications was elegantly illustrated by Cameron et al. (1999) who demonstrated that treatment of tumor cells with an inhibitor of DNA methylation (5AZA) and an inhibitor of HDAC (trichostatin A) produced a synergistic activation of the tumor suppressor gene p16CDKN2A. In accordance with this observation, we have reported that this synergistic gene activation also occurs with other cancer-related genes silenced by aberrant DNA methylation Primeau et al., 2003) . Microarray analysis has been used to investigate the up-or downregulation of a large number of genes in tumor cells after treatment with 5AZA, HDAC inhibitor or a combination of these agents (Suzuki et al., 2002) .
An important question with respect to these different epigenetic events is does DNA methylation direct histone methylation to silence gene expression or does histone methylation direct DNA methylation (Jones and Baylin, 2002; Li, 2002) ? It has been proposed that DNA methylation is the predominant event since in the (upper) . The presence of this complex, deacetylation of lysines in histones and methylation of histone-3 lysine-9 (H-3 Lys-9) by histone methyltransferase converts the nucleosomes into a compact configuration, which prevents the binding of transcription factors. Demethylation of the CpG sites, deacetylation of lysine in histones and methylation of histone-3 lysine-4 (H-3 Lys-4) results in the release of the inhibitory protein complex and an opening of the nucleosome structure, which favors transcription (lower) reactivation of silent tumor suppressor genes, inhibitors of DNA methylation, such as 5AZA, play a more prominent role than an inhibitor of HDAC (Cameron et al., 1999) . On the other hand, Bachman et al. (2003) demonstrated that the methylation of lysine-9 of histone-3 and gene silencing of a tumor suppressor gene can occur prior to DNA methylation in modified tumor cells. However, it is still uncertain if such a sequence of events occurs for other cancer-related genes and in different types of tumors. The aberrant methylation of lysine-9 of histone-3 could be due to a mistake by histone methylase or erroneous binding of a protein that directs the specificity of this enzyme to its substrate.
Epigenetic changes and diagnosis of cancer
Hypermethylation of the promoter region of cancerrelated genes provides a tool for cancer diagnosis. Bisulfite treatment of DNA results in a deamination of cytosine to form uracil; 5-methyl-cytosine is resistant to this chemical treatment. If PCR is performed on the bisulfite-treated DNA, sequence analysis reveals that all the cytosines are replaced by thymine (C to T conversion) whereas 5-methyl-cytosine is not modified (C remains C). This type of analysis permits the identification of the specific positions of 5-methyl-cytosine in genomic DNA. Due to the differences in the DNA sequence of methylated and unmethylated CpGs after bisulfite treatment, it is possible to design specific primers for methylation analysis by PCR (Herman et al., 1996) . This method, called methylation-specific PCR (MSP), is a rapid technique that requires a minimal amount of tissue and can be used to analyse several cancer-related genes in tumors. MSP analysis shows that each tumor type has a profile of methylated genes, which may be used for diagnostic purposes (Tsou et al., 2002; Paz et al., 2003) .
In some patients, dying tumor cells can release fragments of genomic DNA, which can be used as biomarkers for the diagnosis of cancer. Using MSP, it is possible to detect methylated genes released from tumors in the serum of patients (Esteller et al., 1999) . There was a very good correlation between the detection of the methylated gene in serum and the methylation of the identical gene in the primary tumor. This approach has the potential to be used for early diagnosis of cancer and to monitor the response to chemotherapy. Body fluids can also provide material for diagnostic purposes. MSP detected aberrant promoter methylation in sputum of patients with lung cancer, which for some patients correlated with the early diagnosis of this disease (Palmisano et al., 2000) .
Reversibility of epigenetic events provides a target for chemotherapeutic intervention
Genes that suppress tumorigenesis can be silenced by aberrant methylation and aberrant histone acetylation. Since these epigenetic events are reversible they can be potential targets for agents that inhibit DNA methylation or inhibit histone deacetylation. The potent and specific inhibitor of DNA methylation, 5AZA, has been demonstrated to reactivate most of these silent cancer-related genes in human tumor cells (reviewed by Momparler and Bovenzi, 2000) . This fact plus the observations that 5AZA shows promising clinical activity against hematological malignancies (Rivard et al., 1981; Momparler et al., 1986; Pinto and Zagonel, 1993; Kantarjian et al., 1997) and lung cancer (Momparler and Ayoub, 2001) provide the rationale for further investigations into the potential of this demethylating agent in cancer therapy (Brown and Strathdee, 2002) .
It is unlikely that a single agent has the potential to cure malignant disease due to the rapid development of drug resistance to single drug therapy. The interaction of 5AZA with other agents that enhance its antineoplastic activity should also be investigated. The remarkable discovery of the 'cross-talk' between DNA methylation and chromatin remodeling has provided a unique opportunity for therapeutic intervention. Gene silencing by aberrant methylation and histone deacetylation can be reversed by a combination of an inhibitor of DNA methylation and an inhibitor of histone acetylation. This was first demonstrated by Cameron et al. (1999) , who observed a synergistic activation of silent tumor suppressor genes by 5AZA in combination with the HDAC inhibitor. The logical extension of this work is to determine if the combination of these agents produces an enhanced antineoplastic effect. We have observed that 5AZA in combination with HDAC inhibitors produces a synergistic antineoplastic effect against tumor cells (Bovenzi and Momparler, 2001; Boivin et al., 2002; Gagnon et al., 2003; Primeau et al., 2003) and leukemia cells . These in vitro results need to be confirmed in animal models with cancer to provide a solid rationale for clinical investigation in patients with cancer. Currently, both 5AZA and HDAC inhibitors show promising activity in clinical trials as single agents in patients with cancer. Phase I studies on the combination of these epigenetic agents are under development. The future progress of this form of epigenetic therapy of cancer will be followed with great interest.
Conclusion
Epigenetic changes occur frequently during tumor development. The major changes are aberrant DNA methylation and histone modification in chromatin. Both these epigenetic events act in concert to silence the expression of genes that suppress tumorigenesis. The aberrant DNA methylation of some of these target genes can be used for early diagnosis of cancer using MSP. In addition, these epigenetic changes are potential targets for therapeutic intervention using inhibitors of DNA methylation and histone deacetylation. The synergistic activation of tumor suppressor genes and the synergistic in vitro antineoplastic activity by the combination of these epigenetic agents suggest that they have interesting potential for the chemotherapy of cancer.
